Biosimilars Development
Immunology, Oncology
Exploratory / Early DevelopmentStrategic Interest
Key Facts
Indication
Immunology, Oncology
Phase
Exploratory / Early Development
Status
Strategic Interest
Company
About SPIMACO
SPIMACO's mission is to ensure a stable, secure supply of essential medicines for Saudi Arabia and the MENA region through advanced local manufacturing and strategic expansion. The company has achieved market leadership domestically, built a robust international footprint across 21 markets, and established itself as a critical partner in the Kingdom's healthcare transformation. Its strategy is deeply aligned with Vision 2030, focusing on vertical integration, technology transfer, talent development (Saudization), and leveraging its scale to capture growth in both domestic and export markets.
View full company profileTherapeutic Areas
Other Immunology, Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Candidates | Towa Pharmaceutical | Preclinical / Early Development |
| Biosimilars Pipeline | Jubilant Pharmova | Early Development |
| Biosimilars Program | Aspen Pharmacare | Development & Commercial |
| Biosimilar Portfolio | Laboratorios Farmaceuticos Rovi | Clinical Development |